Guides · PeptideU · 9 min read

Somatropin vs Somatrogon: What the Research Compares

The short answer

Somatropin and somatrogon are both prescription growth hormone medicines. Unlike many peptide comparisons, direct head-to-head randomized phase 3 trials exist: somatrogon given once weekly was compared with daily somatropin in children with growth hormone deficiency, with annual height velocity at 12 months as the primary endpoint. Published reports describe non-inferiority results, treatment burden questionnaires, extension data over several years, and injection-site reactions. This page summarises what those studies reported and does not rank either medicine.

Somatropin and somatrogon are both prescription medicines used in the management of growth hormone deficiency, and both are given by subcutaneous injection. Somatropin is recombinant human growth hormone administered daily in standard pediatric regimens. Somatrogon is a long-acting growth hormone molecule designed for once-weekly administration. Unusually for a peptide comparison, the two have been studied directly against each other in randomized phase 3 trials, so this page leads with those head-to-head data before describing each evidence base separately.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medicine, including whether a growth hormone product is appropriate in a given clinical situation. Nothing here is a protocol, and no comparison on this page should be read as a ranking.

Head-to-Head Randomized Trials

Global phase 3 trial: weekly somatrogon vs daily somatropin

The pivotal head-to-head study was a global, open-label, randomized phase 3 trial in prepubertal children with growth hormone deficiency, in which once-weekly somatrogon was compared with once-daily somatropin and the primary endpoint was annual height velocity at 12 months; the researchers reported that weekly somatrogon met the prespecified non-inferiority criterion versus daily somatropin for that endpoint, with adverse events reported at broadly similar frequencies between arms apart from more injection-site reactions in the somatrogon group (PMID 35405011).

Japanese phase 3 trial

A separate randomized phase 3 study conducted in Japanese children with pediatric growth hormone deficiency compared once-weekly somatrogon with once-daily somatropin (Genotropin) and used annual height velocity at 12 months as its efficacy measure; the study reported comparable growth outcomes between the weekly and daily arms, and the authors described the safety profile as generally consistent with growth hormone therapy (PMID 35417909). A plain language summary publication later restated the comparison of weekly somatrogon with daily somatropin in Asian children living with growth hormone deficiency for a non-specialist audience (PMID 41268180).

Treatment burden randomized study

Beyond growth endpoints, a randomized study examined treatment burden directly, comparing weekly somatrogon injections with daily somatropin injections in children with growth hormone deficiency using a patient-reported life interference questionnaire as the outcome; the researchers reported lower overall treatment burden scores with the weekly regimen in that crossover design (PMID 36101713). A plain language summary of that burden comparison was published subsequently to describe the same findings in accessible terms (PMID 39493411).

Summary table of head-to-head trials

Study	Population	Arms as studied	Primary endpoint	Reported result
Global phase 3 (PMID 35405011)	Prepubertal children with growth hormone deficiency	Once-weekly somatrogon vs once-daily somatropin	Annual height velocity at 12 months	Non-inferiority criterion met; more injection-site reactions in the weekly arm
Japanese phase 3 (PMID 35417909)	Japanese children with pediatric growth hormone deficiency	Once-weekly somatrogon vs once-daily somatropin (Genotropin)	Annual height velocity at 12 months	Comparable growth between arms as reported by the study
Treatment burden study (PMID 36101713)	Children with growth hormone deficiency	Weekly somatrogon vs daily somatropin	Patient-reported treatment burden	Lower reported burden scores with the weekly regimen
Phase 2 open-label extension (PMID 36732285)	Children with short stature due to growth hormone deficiency	Once-weekly somatrogon vs once-daily Genotropin, extended	Long-term growth and safety	Growth and safety described after 5 years of treatment

Longer-Term and Extension Data

The dose-finding phase 2 programme that preceded the pivotal trials was carried into an open-label extension in which once-weekly somatrogon was compared with once-daily Genotropin in children with short stature due to growth hormone deficiency, and the authors reported growth and safety observations following 5 years of treatment (PMID 36732285). An extension of the pivotal phase 3 trial reported 3 years of safety and efficacy data in children with growth hormone deficiency who continued somatrogon (PMID 42224388).

In Japan, an open-label extension of the phase 3 study reported efficacy and safety of once-weekly somatrogon following up to 4 years of treatment in Japanese children with growth hormone deficiency (PMID 41183961). Extension studies of this kind follow single-arm continuation rather than maintaining a randomized comparator for the full duration, which is a limitation the reader should keep in mind when interpreting long-term numbers alongside the 12-month randomized endpoints (PMID 35405011).

Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.

Try it free

Observational and Real-World Comparisons

Comparisons outside randomized settings have also been published. A propensity score-matched analysis compared growth outcomes for weekly somatrogon against daily somatropin using clinical trial data matched to records from the KIGS growth database (PMID 42662043). A separate clinical report followed Turkish children transitioned from somatropin to somatrogon and described 6-month clinical outcomes together with follow-up data, framing the question of whether somatrogon behaved differently in that switching context (PMID 42190542).

Health economic modelling has also been published comparing somatrogon once-weekly injections with daily growth hormone injection for paediatric growth hormone deficiency in an Irish setting, reported as a cost-effectiveness and cost-utility analysis (PMID 37527156). Economic analyses depend heavily on local assumptions and are described here only as part of the published literature.

Class, Mechanism and Regulatory Status

Somatropin

Somatropin is recombinant human growth hormone with the same 191 amino acid sequence as the endogenous hormone. It acts at the growth hormone receptor, driving hepatic and peripheral production of insulin-like growth factor 1, which mediates much of the growth response. Somatropin products are approved prescription medicines in the United States, the European Union and many other jurisdictions, with daily subcutaneous administration in standard pediatric growth hormone deficiency regimens; Genotropin was the daily comparator in the Japanese randomized trial (PMID 35417909).

Somatrogon

Somatrogon is a long-acting growth hormone molecule engineered with additional peptide sequence derived from the C-terminal peptide of human chorionic gonadotropin beta chain, which extends its circulating half-life and supports once-weekly dosing. It engages the same growth hormone receptor pathway. Somatrogon is an approved prescription medicine for pediatric growth hormone deficiency in multiple regions including the European Union, Japan, Canada and the United States, with approvals supported by the randomized phase 3 comparison against daily somatropin (PMID 35405011). Whether either product is suitable for a particular patient is a question for a prescribing clinician.

Side-by-side framing

Molecular basis: somatropin replicates native growth hormone; somatrogon is a growth hormone fused to C-terminal peptide sequence for extended exposure.
Administration frequency as studied: daily for somatropin and weekly for somatrogon in the randomized comparisons (PMID 35405011).
Primary efficacy measure used: annual height velocity at 12 months in both pivotal head-to-head trials (PMID 35417909).
Patient-reported outcome studied: treatment burden questionnaire scores comparing the two injection schedules (PMID 36101713).

Tracking research? Log entries with dates, lots and notes: records, never plans.

Get the app

Adverse Events: What Studies Report

In the global randomized phase 3 trial, the researchers reported that adverse events occurred at generally similar rates in the weekly somatrogon and daily somatropin arms, with injection-site reactions, including injection-site pain, reported more frequently among children receiving weekly somatrogon (PMID 35405011). The Japanese randomized phase 3 study described a safety profile consistent with growth hormone therapy across both arms (PMID 35417909).

Longer follow-up added to this picture. The 3-year extension of the pivotal phase 3 trial reported safety alongside efficacy in children continuing somatrogon (PMID 42224388), and the Japanese open-label extension reported safety across up to 4 years of once-weekly somatrogon treatment (PMID 41183961). The 5-year phase 2 extension likewise reported safety observations over extended exposure in children treated with once-weekly somatrogon or once-daily Genotropin (PMID 36732285).

A published case series described reversible injection-site lipoatrophy in children with growth hormone deficiency treated with long-acting growth hormone (somatrogon), reporting that the lipoatrophic changes resolved in the cases followed (PMID 41261869). Case series describe observations in a small number of patients and do not establish frequency. A clinical follow-up of Turkish children transitioned from somatropin to somatrogon reported 6-month outcomes and follow-up data in that switching population (PMID 42190542).

Interpreting the Comparison

Several points shape how the head-to-head literature should be read. The pivotal trials were open-label, which is common when injection frequency differs between arms but means blinding did not protect patient-reported outcomes such as treatment burden (PMID 36101713). The primary endpoint in both pivotal comparisons was annual height velocity at 12 months rather than final adult height (PMID 35405011). Non-inferiority designs test whether an outcome falls within a prespecified margin and are not designed to demonstrate superiority in either direction. Real-world and matched-cohort analyses, such as the propensity score-matched comparison against KIGS registry records, carry the residual confounding limitations inherent to non-randomized data (PMID 42662043).

The published evidence base is concentrated in pediatric growth hormone deficiency. Questions about other indications, about adults, or about individual patient circumstances are not answered by the trials summarised here and belong with a prescribing clinician who can review the full labelling and the individual clinical picture.

Want the full course? Every compound, evidence-graded and cited, inside PeptideU.

Start learning free

References

Frequently asked questions

Has somatrogon been compared directly with somatropin in a randomized trial?▾

Yes. A global open-label randomized phase 3 trial compared once-weekly somatrogon with once-daily somatropin in prepubertal children with growth hormone deficiency, using annual height velocity at 12 months as the primary endpoint, and reported that the non-inferiority criterion was met (PMID 35405011). A separate randomized phase 3 study ran the same comparison in Japanese children (PMID 35417909).

What primary endpoint did the head-to-head trials use?▾

Both pivotal head-to-head studies used annual height velocity at 12 months as the primary efficacy measure in children with growth hormone deficiency (PMID 35405011). The Japanese randomized phase 3 study applied the same 12-month height velocity framework when comparing once-weekly somatrogon with once-daily Genotropin (PMID 35417909). Final adult height was not the primary endpoint in those reports.

What did studies report about injection-site reactions?▾

The global randomized phase 3 trial reported injection-site reactions, including injection-site pain, more frequently in children receiving weekly somatrogon than daily somatropin, while overall adverse event rates were broadly similar (PMID 35405011). A separate case series described reversible injection-site lipoatrophy in children treated with somatrogon, with the changes resolving in the reported cases (PMID 41261869).

Is there evidence beyond 12 months?▾

Yes. An extension of the pivotal phase 3 trial reported 3 years of safety and efficacy data in children continuing somatrogon (PMID 42224388), a Japanese open-label extension reported outcomes following up to 4 years of treatment (PMID 41183961), and a phase 2 open-label extension reported results after 5 years comparing weekly somatrogon with daily Genotropin (PMID 36732285).

What was studied about treatment burden?▾

A randomized study compared weekly somatrogon injections with daily somatropin injections in children with growth hormone deficiency using a patient-reported life interference questionnaire, and researchers reported lower overall treatment burden scores with the weekly schedule (PMID 36101713). A plain language summary publication later restated those burden findings for a general readership (PMID 39493411).

What is the regulatory status of each medicine?▾

Somatropin products are approved prescription recombinant human growth hormone medicines in many jurisdictions and served as the daily comparator in the randomized trials (PMID 35417909). Somatrogon is an approved prescription long-acting growth hormone for pediatric growth hormone deficiency in multiple regions, with approval supported by the randomized phase 3 comparison (PMID 35405011). Suitability questions belong with a prescribing clinician.

Has any non-randomized comparison been published?▾

Yes. A propensity score-matched analysis compared growth outcomes for weekly somatrogon with daily somatropin using clinical data matched against KIGS registry records (PMID 42662043), and a clinical report described 6-month outcomes with follow-up in Turkish children transitioned from somatropin to somatrogon (PMID 42190542). Non-randomized designs carry residual confounding limitations.

The PeptideU app

Track it. Calculate it. Actually understand it.

Research trackerLog every entry with dates, lots and notes: records, never plans.

CalculatorsReconstitution, units and dilution maths without the guesswork.

The UniversityEvery compound explained, evidence-graded, cited to the literature.

Get started freePeptideU Premium: $9.99/mo for the full curriculum, advanced tracking & giveaways

Download on theApp Store — Free Get it onGoogle Play

References

Keep learning

18+ · Educational purposes only
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.